
|Videos|September 21, 2017
What Are the Next Steps for Iclaprim?
Author(s)Contagion® Editorial Staff
David Huang, PhD, MD, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections.
Advertisement
David Huang, PhD, MD, chief medical officer at Motif Bio, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections. Dr. Huang shares that if the results of REVIVE 2 are favorable, then he and his team will submit a new drug application to the US Food and Drug Administration in the first half of next year.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Initiatives Look to Strengthen Vaccine Policy and Governance in US
2
European Commission Approves Glecaprevir/Pibrentasvir for Hepatitis C
3
Infectious Disease Regulatory Watch: June Highlights
4
Efflux Pump Inhibitor Restores Azithromycin Activity Against Multidrug-Resistant Gram-Negative Pathogens
5























































































































































































































